This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Harvey Raphan, MD; Marijke H. Adams, PharmD, PhD
GD Searle & Co Skokie, Ill

JAMA. 1995;273(24):1905-1906.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We thank Dr Pulini for her interest in this issue. Laboratory test interferences have been reported by Jelic-Ivanovic et al¹ and in the complete prescribing information for several NSAIDs, including etodolac (Lodine, Wyeth-Ayerst Laboratories, Philadelphia, Pa), naproxen sodium (Anaprox, Naprosyn; Syntex Puerto Rico Inc), fenoprofen calcium (Nalfon, Eli Lilly and Co, Indianapolis, Ind), and tolmetin sodium (Tolectin, McNeil Pharmaceuticals, Raritan, NJ), and GD Searle & Co has received reports of alleged false-positive benzodiazepine test results from standard urine toxicology screens for drugs of abuse in patients taking oxaprozin. Based on our investigation into this matter, the prescribing information for oxaprozin was updated in November 1993 to reflect the new information. The 1994 Physicians' Desk Reference (PDR) had already gone to press at that time; current information appears in the 1995 PDR and in the PDR on CD-ROM.²

Although oxaprozin is not chemically related to the benzodiazepines, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?